Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications

Cancers, Journal Year: 2024, Volume and Issue: 16(6), P. 1213 - 1213

Published: March 20, 2024

Circulating tumor cells (CTCs) are released from the primary and metastatic intravasate into blood or lymphatic vessels, where they transported to distant sites act as seeds that initiate cancer metastases development of further lesions. Recent advances in CTC research have shown their relevance prognostic markers for early disease detection, predictive biomarkers relapse, response medical intervention therapy. The rapidly evolving landscape biology has opened new avenues understanding progression, metastasis, treatment response. Additionally, translating these findings clinical applications holds promise improving diagnostics, prognosis, personalized therapeutic strategies. This review discusses significance CTCs associated challenges. We explore recent developments detection characterization implications practice.

Language: Английский

---

Development of Personalized Strategies for Precisely Battling Malignant Melanoma

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(9), P. 5023 - 5023

Published: May 4, 2024

Melanoma is the most severe and fatal form of skin cancer, resulting from multiple gene mutations with high intra-tumor inter-tumor molecular heterogeneity. Treatment options for patients whose disease has progressed beyond ability surgical resection rely on currently accepted standard therapies, notably immune checkpoint inhibitors targeted therapies. Acquired resistance to these therapies treatment-associated toxicity necessitate exploring novel strategies, especially those that can be personalized specific and/or populations. Here, we review current landscape progress explore what oncology techniques may entail in scope melanoma. Our purpose provide an up-to-date summary tools at our disposal work circumvent common barriers faced when battling

Language: Английский

---

Disulfidptosis, A Novel Cell Death Pathway: Molecular Landscape and Therapeutic Implications

Aging and Disease, Journal Year: 2024, Volume and Issue: unknown, P. 0 - 0

Published: Jan. 1, 2024

Programmed cell death is pivotal for several physiological processes, including immune defense. Further, it has been implicated in the pathogenesis of developmental disorders and onset numerous diseases. Multiple modes programmed death, apoptosis, pyroptosis, necroptosis, ferroptosis, have identified, each with their own unique characteristics biological implications. In February 2023, Liu Xiaoguang his team discovered "disulfidptosis," a novel pathway death. Their findings demonstrated that disulfidptosis triggered glucose-starved cells exhibiting high expression protein called SLC7A11. Furthermore, marked by drastic imbalance NADPH/NADP+ ratio abnormal accumulation disulfides like cystine. These changes ultimately lead to destabilization F-actin network, causing Given SLC7A11 key feature certain cancers, these indicate could serve as basis innovative anti-cancer therapies. Hence, this review delves into discovery disulfidptosis, its underlying molecular mechanisms metabolic regulation, prospective applications disease treatment.

Language: Английский

---

Cisplatin Resistance and Metabolism: Simplification of Complexity

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 3082 - 3082

Published: Sept. 4, 2024

Cisplatin is one of the most well-known anti-cancer drugs and has demonstrated efficacy against numerous tumor types for many decades. However, a key challenge with cisplatin, as any chemotherapeutic agent, development resistance resultant loss efficacy. This often associated metabolic alterations that allow insensitive cells to divide survive under treatment. These adaptations could vary greatly among different may seem questionable incomprehensible at first glance. Here we discuss disturbances in glucose, lipid, amino acid metabolism cisplatin-resistant well roles ferroptosis autophagy acquiring this type drug intolerance.

Language: Английский

---

Clinical Approaches for the Management of Skin Cancer: A Review of Current Progress in Diagnosis, Treatment, and Prognosis for Patients with Melanoma

Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 707 - 707

Published: Feb. 19, 2025

Melanoma represents a significant public health challenge due to its increasing incidence and potential for metastasis. This review will explore the current clinical approaches management of melanoma, focusing on advancements in diagnosis, treatment, prognosis. Methods early detection accurate staging have been enhanced by new diagnostic strategies. Treatment modalities expanded beyond traditional surgical excision include targeted therapy immunotherapy. Prognostic assessment has benefited from development novel biomarkers genetic profiling. highlight progress made multidisciplinary underscoring importance continuous research improve patient outcomes.

Language: Английский

---

Multi-Omics Analysis of the Anoikis Gene CASP8 in Prostate Cancer and Biochemical Recurrence (BCR)

Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 661 - 661

Published: March 7, 2025

Background: Prostate cancer, as an androgen-dependent malignant tumor in older men, has attracted the attention of a wide range clinicians. BCR remains significant challenge following early prostate cancer treatment. Methods: The specific expression pattern Anoikis gene set cells was first explored by single-cell and spatial transcriptomics analysis. Genes causally associated with were screened using Summary-data-based Mendelian Randomization (SMR). Subsequently, we role mechanism CASP8 defined new cell type: T cell. We constructed prediction model that can better predict differences various aspects clinical subgroups, microenvironments, immune checkpoints, drug sensitivities, tumor-immune circulations between high- low-risk groups. results SMR analysis indicated could increase risk cancer. Based on differential genes CASP8-positive -negative cells, four-gene prognostic 5-year AUC 0.713. Results: revealed high-risk patients had characteristics such higher purity, rate, downregulated SIRPA unique sensitivity. Conclusions: In summary, may be potential biomarker for

Language: Английский

---

Inhibition of KIAA1429/HK1 axis enhances the sensitivity of liver cancer cells to sorafenib by regulating the Warburg effect

Biochemical Pharmacology, Journal Year: 2024, Volume and Issue: 227, P. 116419 - 116419

Published: July 10, 2024

Language: Английский

---

Combination of circulating tumor cells and 18F‐FDG PET/CT for precision diagnosis in patients with non‐small cell lung cancer

Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(18)

Published: Sept. 1, 2024

Abstract Purpose To investigate the value of 2‐deoxy‐18f‐fluorodeoxyglucose (18F‐FDG) positron emission tomography/computed tomography (PET/CT) and circulating tumor cells (CTCs) for differential diagnosis patients with benign lung diseases those NSCLC. explore phenotypic heterogeneity CTCs their correlation FDG uptake in Stage I–IV Methods Blood specimens from primary NSCLC were collected detection subtypes (epithelial, mixed, mesenchymal) analyzed 18F‐FDG PET/CT metabolic parameters, including maximum standardized (SUV max ), standard (SUL), volume lesion (MTV), total glycolysis (TLG). Clinical data age, gender, smoking history, size, TNM stage pathology type also collected. The two method alone combination malignant was comparatively analyzed. Finally, differences CTC its different stages compared, parameters correlated subtypes. Results There a 65 pulmonary diseases, 12 53 mean age 67 ± 10 (38–89 years), 27 females 38 males. 31 (22 males 9 females) had long history smoking. size largest diameter all single lesions 36 22 mm range 10–108 mm. Seven out inflammatory granulomatous 5 pseudotumours. Twenty‐four adenocarcinomas 29 squamous carcinomas. Twelve I, II, 17 III 14 IV. SUV , SUL, MTV, TLG, CTCs, epithelial mixed valuable malignant. TLG combined statistically other diagnostic methods ( p < 0.05) higher than any criteria. In I NSCLC, only Z = −2.188 0.039) −3.020 0.014) certain efficacy, there no statistical difference between them 0.480). Only mesenchymal differed number who developed distant metastases non‐distant metastases. Epithelial r 0.333, 0.015) SUL 0.374, 0.006). Mmesenchymal MTV 0.342, 0.018) 0.319, 0.02). Further subgroup analyses revealed 0.543, 0.009) 0.552, 0.008), 0.622, 0.003), 0.652, 0.460, 0.031), 0.472, 0.027) early group (Stage I–II). associated 0.369, 0.041), 0.415, 0.02) intermediate‐late III–IV). Conclusion Both PET demonstrated combining could enhance efficacy. showed greater distinguishing patients, exhibited positive while TLG. Besides, stronger correlations I–II III–IV IV cases displayed CTCs.

Language: Английский

---

Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care

Cancers, Journal Year: 2024, Volume and Issue: 16(6), P. 1151 - 1151

Published: March 14, 2024

Although immunotherapy has revolutionized cancer care, there is still an urgent need to enhance its efficacy and ensure safety. A correct theory proper scientific method empower pertinent research enable effective efficient drug versus therapy development for patient care. In this perspective, we revisit the concept of immune privilege in a cell normal cell, as well stem cell. We re-examine whether immunotherapies are efficacious due their anti-cancer and/or modulatory mechanisms. reassess why checkpoint inhibitors (CPIs) not equal. reconsider one can attribute utility specific subtypes futility certain tumor/immune compartments, components, microenvironments. propose ways means advance beyond CPIs by combining anti-PD1/L1 with various other treatment modalities according appropriate theory, e.g., origin cancer, based on available clinical evidence, randomized trials. predict that will facilitate design better safer improved selection use right type at time optimize benefits minimize potential toxic effects complications.

Language: Английский

---

MLIP and Its Potential Influence on Key Oncogenic Pathways

Cells, Journal Year: 2024, Volume and Issue: 13(13), P. 1109 - 1109

Published: June 26, 2024

Muscle-enriched A-type lamin-interacting protein (MLIP) is an emerging involved in cellular homeostasis and stress adaptation. Eukaryotic cells regulate various processes, including metabolism, DNA repair, cell cycle progression, to maintain homeostasis. Disruptions this can lead diseases such as cancer, characterized by uncontrolled growth division. This review aims explore for the first time unique role MLIP may play cancer development given its interactions with PI3K/Akt/mTOR pathway, p53, MAPK9, FOXO transcription factors, all critical regulators of tumor suppression. We discuss current understanding MLIP's involvement pro-survival pathways potential implications cells' metabolic remodeling dysregulated Additionally, we examine a novel therapeutic target treatment. shed light on impact biology contribute developing innovative strategies.

Language: Английский

---